Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Clar, H; Langsenlehner, U; Krippl, P; Renner, W; Leithner, A; Gruber, G; Hofmann, G; Yazdani-Biuki, B; Langsenlehner, T; Windhager, R.
A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients.
Breast Cancer Res Treat. 2008; 111(3):449-452
Doi: 10.1007/s10549-007-9808-0
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Clar Heimo
- Langsenlehner Uwe
- Co-Autor*innen der Med Uni Graz
- Gruber Gerald
- Hofmann Guenter
- Langsenlehner Tanja
- Leithner Andreas
- Renner Wilfried
- Windhager Reinhard
- Yazdani-Biuki Babak
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Breast cancer is the most frequently diagnosed cancer among women in western countries and bone metastases of breast cancer cause significant morbidity. G proteins are important components of a multitude of transmembrane receptors and are involved in the regulation of intracellular signaling pathways such as parathormone receptors 1 and 2 (PTH1 and 2), extracellular calcium-sensing receptor, the calcitonin receptor and the OPG/RANKL-system. A common polymorphism in the gene encoding the G protein beta3-subunit, GNB3 825C > T, has been linked to increased G protein activation. To analyse the role of this polymorphism in bone metastasis of breast cancer, we determined GNB3 825C > T genotypes in 500 female breast cancer patients. According to breast cancer staging, patients were divided in three groups, representing patients without metastases (n = 250), those with metastases other than bone (n = 117), and those with bone metastasis (n = 133). Frequency of the GNB3 825 TT genotype was significantly lower among patients with bone metastases (3.1%) than among those with other metastases (12.8%; P = 0.004) or no metastases (13.3%; P < 0.001). In a Cox regression analysis, relative risk of the GNB3 TT genotype for bone metastasis was 0.22 (95% CI 0.08-0.61; P = 0.004) for bone metastasis. We conclude that the homozygous GNB3 825 TT genotype may be protective against development of bone metastasis in breast cancer patients. The precise mechanism for this remains to be determined, but could be due to a direct involvement of G protein-coupled receptors in bone metabolism.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Bone Neoplasms - genetics
- Breast Neoplasms - genetics
- Female - genetics
- Gene Expression Regulation, Neoplastic - genetics
- Gene Frequency - genetics
- Genetic Predisposition to Disease - genetics
- Heterotrimeric GTP-Binding Proteins - genetics
- Humans - genetics
- Middle Aged - genetics
- Neoplasm Staging - genetics
- Polymorphism, Genetic - genetics
- Proportional Hazards Models - genetics
- Retrospective Studies - genetics
- Risk Assessment - genetics
- Risk Factors - genetics
- Time Factors - genetics
- Find related publications in this database (Keywords)
- breast cancer
- bone metastases
- GNB3
- gene polymorphism